139 related articles for article (PubMed ID: 23775009)
1. Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers.
Falzarano R; Viggiani V; Michienzi S; Longo F; Tudini S; Frati L; Anastasi E
Tumour Biol; 2013 Oct; 34(5):3093-100. PubMed ID: 23775009
[TBL] [Abstract][Full Text] [Related]
2. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Lumipulse® G1200 for the measurement of six tumor markers: Comparison with AIA® 2000.
de Rancher MR; Oudart JB; Maquart FX; Monboisse JC; Ramont L
Clin Biochem; 2016 Nov; 49(16-17):1302-1306. PubMed ID: 27521619
[TBL] [Abstract][Full Text] [Related]
4. Comparison of LUMIPULSE(®) G1200 With Kryptor and Modular E170 for the Measurement of Seven Tumor Markers.
Marlet J; Bernard M
J Clin Lab Anal; 2016 Jan; 30(1):5-12. PubMed ID: 25283278
[TBL] [Abstract][Full Text] [Related]
5. A novel immunoassay for the quantization of CYFRA 21-1 in human serum.
He A; Liu TC; Dong ZN; Ren ZQ; Hou JY; Li M; Wu YS
J Clin Lab Anal; 2013 Jul; 27(4):277-83. PubMed ID: 23852784
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
Gwak HK; Lee JH; Park SG
Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
[TBL] [Abstract][Full Text] [Related]
8. Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19-9, CA15-3, CA125, PSA, HE4, Cyfra 21-1, and ProGRP) in primary care centers in Korea: A cross-sectional retrospective study.
Nah EH; Cho S; Park H; Kim S; Kwon E; Cho HI
Health Sci Rep; 2023 Feb; 6(2):e1107. PubMed ID: 36789402
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
[TBL] [Abstract][Full Text] [Related]
11. Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers.
Nishizono I; Iida S; Suzuki N; Kawada H; Murakami H; Ashihara Y; Okada M
Clin Chem; 1991 Sep; 37(9):1639-44. PubMed ID: 1716538
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
13. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantitation of cytokeratin-19 fragment and carcinoembryonic antigen in human serum via quantum dot-doped nanoparticles.
Chen Z; Liang R; Guo X; Liang J; Deng Q; Li M; An T; Liu T; Wu Y
Biosens Bioelectron; 2017 May; 91():60-65. PubMed ID: 27988480
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
16. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
[TBL] [Abstract][Full Text] [Related]
17. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
19. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(7):4369-71. PubMed ID: 23992005
[TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum.
Patel JL; Erickson JA; Roberts WL; Grenache DG
Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
